Literature DB >> 25285408

Pushing the pedal to the metal: should we accelerate infliximab therapy for patients with severe ulcerative colitis?

Hans H Herfarth1, Gerhard Rogler2, Peter D R Higgins3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25285408      PMCID： PMC4363249          DOI： 10.1016/j.cgh.2014.09.045

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   11.382


× No keyword cloud information.
  18 in total

1.  Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee.

Authors:  Asher Kornbluth; David B Sachar
Journal:  Am J Gastroenterol       Date:  2010-01-12       Impact factor: 10.864

2.  Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis.

Authors:  Adedigbo A Fasanmade; Omoniyi J Adedokun; Joyce Ford; Danika Hernandez; Jewel Johanns; Chuanpu Hu; Hugh M Davis; Honghui Zhou
Journal:  Eur J Clin Pharmacol       Date:  2009-09-16       Impact factor: 2.953

3.  The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial.

Authors:  Rene Westhovens; David Yocum; John Han; Alberto Berman; Ingrid Strusberg; Piet Geusens; Mahboob U Rahman
Journal:  Arthritis Rheum       Date:  2006-04

4.  Infliximab for induction and maintenance therapy for ulcerative colitis.

Authors:  Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

Review 5.  Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms.

Authors:  Ingrid Ordás; Diane R Mould; Brian G Feagan; William J Sandborn
Journal:  Clin Pharmacol Ther       Date:  2012-02-22       Impact factor: 6.875

Review 6.  Meta-analysis: peri-operative anti-TNFα treatment and post-operative complications in patients with inflammatory bowel disease.

Authors:  N Narula; D Charleton; J K Marshall
Journal:  Aliment Pharmacol Ther       Date:  2013-04-14       Impact factor: 8.171

7.  Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.

Authors:  David Laharie; Arnaud Bourreille; Julien Branche; Matthieu Allez; Yoram Bouhnik; Jerome Filippi; Frank Zerbib; Guillaume Savoye; Maria Nachury; Jacques Moreau; Jean-Charles Delchier; Jacques Cosnes; Elena Ricart; Olivier Dewit; Antonio Lopez-Sanroman; Jean-Louis Dupas; Franck Carbonnel; Gilles Bommelaer; Benoit Coffin; Xavier Roblin; Gert Van Assche; Maria Esteve; Martti Färkkilä; Javier P Gisbert; Philippe Marteau; Stephane Nahon; Martine de Vos; Denis Franchimont; Jean-Yves Mary; Jean-Frederic Colombel; Marc Lémann
Journal:  Lancet       Date:  2012-10-10       Impact factor: 79.321

8.  Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis.

Authors:  C H Seow; A Newman; S P Irwin; A H Steinhart; M S Silverberg; G R Greenberg
Journal:  Gut       Date:  2010-01       Impact factor: 23.059

9.  Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.

Authors:  C S J Probert; S D Hearing; S Schreiber; T Kühbacher; S Ghosh; I D R Arnott; A Forbes
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

10.  Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management.

Authors:  Axel Dignass; James O Lindsay; Andreas Sturm; Alastair Windsor; Jean-Frederic Colombel; Mathieu Allez; Gert D'Haens; André D'Hoore; Gerassimos Mantzaris; Gottfried Novacek; Tom Oresland; Walter Reinisch; Miquel Sans; Eduard Stange; Severine Vermeire; Simon Travis; Gert Van Assche
Journal:  J Crohns Colitis       Date:  2012-10-03       Impact factor: 10.020
View more
  10 in total

1.  Systematic Review: Efficacy and Safety of Accelerated Induction Regimes in Infliximab Rescue Therapy for Hospitalized Patients with Acute Severe Colitis.

Authors:  S Sebastian; S Myers; S Nadir; S Subramanian
Journal:  Dig Dis Sci       Date:  2018-12-07       Impact factor: 3.199

2.  Improving IBD Care: A Personalized Approach to Management.

Authors:  Stephen B Hanauer
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-03

3.  High-Dose Infliximab Rescue Therapy for Hospitalized Acute Severe Ulcerative Colitis.

Authors:  Cong Dai; Min Jiang; Ming-Jun Sun
Journal:  Dig Dis Sci       Date:  2019-03-04       Impact factor: 3.199

4.  Post-induction infliximab trough levels and disease activity in the clinical evolution of pediatric ulcerative colitis.

Authors:  Hillary Moore; Pasquale Dolce; Nina Devas; Robert Baldassano; Massimo Martinelli
Journal:  United European Gastroenterol J       Date:  2020-03-12       Impact factor: 4.623

5.  Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis.

Authors:  Matthew C Choy; Dean Seah; David M Faleck; Shailja C Shah; Che-Yung Chao; Yoon-Kyo An; Graham Radford-Smith; Talat Bessissow; Marla C Dubinsky; Alexander C Ford; Leonid Churilov; Neville D Yeomans; Peter P De Cruz
Journal:  Inflamm Bowel Dis       Date:  2019-06-18       Impact factor: 5.325

6.  High-Dose Infliximab Rescue Therapy for Hospitalized Acute Severe Ulcerative Colitis Does Not Improve Colectomy-Free Survival.

Authors:  Che-Yung Chao; Alex Al Khoury; Achuthan Aruljothy; Sophie Restellini; Jonathan Wyse; Waqqas Afif; Alain Bitton; Peter L Lakatos; Talat Bessissow
Journal:  Dig Dis Sci       Date:  2018-11-16       Impact factor: 3.199

Review 7.  Contemporary Management of Ulcerative Colitis.

Authors:  Rohini Vanga; Millie D Long
Journal:  Curr Gastroenterol Rep       Date:  2018-03-27

8.  Practice pattern variability in the management of acute severe colitis: a UK provider survey.

Authors:  Shaji Sebastian; Jessica Lisle; Sreedhar Subramanian; Anjan Dhar; Achut Shenoy; Jimmy Limdi; Jeffrey Butterworth; Patrick B Allen; Sunil Samuel; Gordon Moran; Richard Shenderey; Gareth Parkes; Tim Raine; Alan J Lobo; Nicholas A Kennedy
Journal:  Frontline Gastroenterol       Date:  2019-08-17

9.  Comparison of medium to long-term outcomes of acute severe ulcerative colitis patients receiving accelerated and standard infliximab induction.

Authors:  David J Gibson; Jayne Doherty; Mairead McNally; John Campion; Denise Keegan; Aine Keogh; Una Kennedy; Kathryn Byrne; Laurence J Egan; Susan McKiernan; FInbar MacCarthy; Subhasish Sengupta; Juliette Sheridan; Hugh E Mulcahy; Garret Cullen; Eoin Slattery; David Kevans; Glen A Doherty
Journal:  Frontline Gastroenterol       Date:  2019-12-13

10.  The Continental Divide: Anti-TNF Use in Pediatric IBD Is Different in North America Compared to Other Parts of the World.

Authors:  Peter C Church; Jeffrey Hyams; Frank Ruemmele; Lissy de Ridder; Dan Turner; Anne M Griffiths
Journal:  Can J Gastroenterol Hepatol       Date:  2018-06-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.